论文部分内容阅读
目的:探讨GDP与CHOP方案治疗非特异性外周T细胞淋巴瘤的临床疗效,为临床治疗提供参考。方法:选择2013年1月到2016年1月我院收治的非特异性外周T细胞淋巴瘤患者80例,随机分为GDP组(n=40)和CHOP组(n=40)。GDP组患者给予GDP治疗方案(顺铂+吉西他滨+强的松),CHOP组患者给予CHOP治疗方案(多柔比星+环磷酰胺+长春新碱+强的松),两组患者均治疗6个疗程。比较两组患者临床疗效和不良反应发生情况。结果:GDP组患者近期疗效总有效率为75.00%,明显高于CHOP组的45.00%,差异具有统计学意义(P<0.05)。GDP组患者的无进展生存期(PFS)、总生存期(OS)分别为(9.69±1.50)月和(16.72±3.06)月,明显大于CHOP组的(5.16±1.38)月和(10.98±3.37)月,差异具有统计学意义(P<0.05)。GDP组患者恶心呕吐的发生率为72.50%,明显低于CHOP组的97.50%,差异具有统计学意义(P<0.05)。结论:GDP方案治疗非特异性外周T细胞淋巴瘤的临床疗效明显优于CHOP方案,且不良反应发生率低,值得在临床上推广应用。
Objective: To investigate the clinical efficacy of GDP and CHOP regimen in the treatment of nonspecific peripheral T cell lymphoma, and provide a reference for clinical treatment. Methods: Eighty nonspecific peripheral T cell lymphoma patients admitted to our hospital from January 2013 to January 2016 were randomly divided into GDP group (n = 40) and CHOP group (n = 40). Patients in the GDP group were given GDP treatment (cisplatin + gemcitabine + prednisone), patients in the CHOP group were treated with CHOP (doxorubicin + cyclophosphamide + vincristine + prednisone), and both were treated for 6 A course of treatment. The clinical efficacy and adverse reactions of the two groups were compared. Results: The total effective rate of short term effect in GDP group was 75.00%, which was significantly higher than that in CHOP group (45.00%), the difference was statistically significant (P <0.05). The progression free survival (PFS) and overall survival (OS) of the GDP group were (9.69 ± 1.50) months and (16.72 ± 3.06) months, respectively, significantly higher than those of the CHOP group (5.16 ± 1.38) and (10.98 ± 3.37 ) Month, the difference was statistically significant (P <0.05). The incidence of nausea and vomiting in the GDP group was 72.50%, which was significantly lower than that in the CHOP group (97.50%, P <0.05). Conclusion: The GDP treatment of non-specific peripheral T-cell lymphoma clinical efficacy was significantly better than the CHOP program, and the incidence of adverse reactions is low, it is worth popularizing the clinical application.